Russian 
English 
Chinese 
French Блог
MSC Therapy for Diabetic Foot Ulcers: 2026 Mechanism, Hydrogel Delivery, and Real-World Trial Outcomes
2026 medical update on MSC therapy for diabetic foot ulcers: M2 macrophage polarization, EXO-miR3671 angiogenesis, hydrogel delivery, UC-MSC vs ADSC head-to-head, 47-RCT meta-analysis, and cost-effectiveness vs amputatio…
Aug 18, 2026
The First FDA-Approved Stem Cell Therapy for Type 1 Diabetes: What Zimislecel Means for Patients in 2026
Zimislecel (VX-880) is the first stem cell-derived islet therapy to reach the FDA, and the September 2025 NEJM paper showed 12 of 12 patients achieving insulin independence. Here’s what it means for T1D patients in 2026,…
Aug 13, 2026
Healing Chronic Wounds with Stem Cells: A New Frontier for Diabetic Patients
Diabetic wounds that refuse to heal affect hundreds of thousands of Thais. Discover how exosome therapy and MSC treatment are giving patients a real path to recovery.
May 29, 2026
Can Stem Cells Reverse Diabetes? What Thai Patients Should Know in 2026
Diabetes affects millions across Thailand. Can stem cell therapy help reverse it? Our Bangkok clinic shares real patient outcomes, THB pricing, and what the latest research says about stem cells for diabetes in 2026.
May 25, 2026
Stem Cells vs. Type 1 Diabetes: Are We on the Cusp of a Cure?
Type 1 diabetes has long been considered a lifelong condition, requiring constant management and insulin therapy. However, recent developments in stem cell research are challenging this notion and offering hope for a pot…
Feb 10, 2025
Groundbreaking Advances in Stem Cell Therapy for Type 1 Diabetes
In a landmark development for stem cell research and diabetes treatment, Vertex Pharmaceuticals has achieved remarkable success with their investigational therapy VX-880 for type 1 diabetes (T1D). This breakthrough, base…
Jan 9, 2025
На шаг ближе к терапии стволовыми клетками при диабете 1 типа
Ученые разрабатывают многообещающий подход к лечению диабета 1 типа с помощью стволовых клеток для создания клеток, продуцирующих инсулин (называемых бета-клетками), которые могут заменить нефункциональные клетки поджелудочной железы.
Aug 3, 2021
Мышечный ген связан с диабетом 2 типа
Люди с диабетом 2 типа, как правило, имеют более низкую мышечную функцию, чем другие. Теперь исследовательская группа обнаружила, что при диабете 2 типа особый ген имеет большое значение для способности мышечных стволовых клеток создавать новые зрелые мышечные клетки.
May 5, 2021
Page 1 of 1 — 8 posts